10-K: Myomo Inc. Reports Full Year 2023 Results, Highlights Medicare Reimbursement Milestone

Myomo, Inc. reports a 20% increase in product revenue for 2023 and anticipates achieving cash flow breakeven by the fourth quarter of 2024, driven by Medicare reimbursement changes.

Summary

• Myomo, Inc., a medical robotics company, reported a 20% increase in product revenue for the year ended December 31, 2023, reaching $17.5 million, compared to $14.6 million in 2022.
• Total revenue, including license revenue, increased by 24% to $19.2 million in 2023 from $15.6 million in 2022.
• The company's gross margin improved to 68.5% in 2023 from 65.9% in 2022, primarily due to higher average selling prices and license revenue.
• Myomo incurred a net loss of $8.1 million in 2023, compared to a net loss of $10.7 million in 2022.
• Operating expenses increased slightly by 2% to $21.4 million in 2023.
• The company expects to achieve cash flow breakeven on a quarterly basis by the fourth quarter of 2024, contingent on hiring additional staff and managing supply chain effectively.
• As of December 31, 2023, Myomo had $8.9 million in cash, cash equivalents, and short-term investments.
• A registered direct offering in January 2024 generated net proceeds of approximately $5.4 million.
• The company's backlog of authorized MyoPro units was 230 as of December 31, 2023, with an estimated maximum potential revenue value of $9.9 million.
• Medicare reimbursement for the MyoPro on a lump sum basis began on January 1, 2024, with final payment determinations published on February 29, 2024, at approximately $33,500 for L8701 and $65,900 for L8702, effective April 1, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and a clear path to profitability, but also acknowledges ongoing losses and risks. The Medicare reimbursement change is a significant positive catalyst.

Positives

• The company experienced a significant increase in product revenue and total revenue.
• Gross margin improved, indicating better profitability on sales.
• The transition to lump sum Medicare reimbursement is expected to drive revenue growth.
• The company has a substantial backlog of authorized units, representing future revenue potential.
• Recent capital raises have strengthened the company's financial position.
• The company is actively expanding its clinical, reimbursement, and manufacturing capacity.

Negatives

• The company continues to incur net losses, although the loss decreased compared to the previous year.
• Operating expenses remain high, impacting overall profitability.
• The company is dependent on a single insurer for a significant portion of its revenue, creating a concentration risk.
• The company relies on a single third-party manufacturer for key subassemblies.

Risks

• The company's ability to achieve cash flow breakeven is dependent on hiring additional staff and managing supply chain effectively.
• Adverse changes in the reimbursement policies of a major insurer could negatively impact revenue.
• The company's reliance on a single third-party manufacturer for key subassemblies poses a supply chain risk.
• The market for myoelectric braces is new and the rate of adoption is uncertain.
• Defects in products or software could adversely affect operations.
• The company is subject to extensive governmental regulations, and failure to comply could lead to product recalls.
• The company depends on certain patents that are licensed to them, and any loss of rights could prevent manufacturing.
• The company's internal computer systems may be subject to cyber-attacks or security breaches.
• The market price of the company's common stock has been and may continue to be volatile.

Future Outlook

The company anticipates achieving cash flow breakeven on a quarterly basis by the fourth quarter of 2024, contingent on hiring additional staff and managing supply chain effectively. The company also plans to introduce the MyoPro3 and MyoPal device for pediatric use at a future date.

Management Comments

• The company believes it is achievable to be cash flow breakeven on a quarterly basis by the fourth quarter of 2024.
• Management plans to hire more than 50 employees by the end of the second quarter of 2024 to increase clinical, reimbursement, and manufacturing capacity.
• The company expects that claims will continue to be reviewed on a case-by-case basis for the near term.

Industry Context

The announcement comes as the medical device industry is seeing increased focus on wearable robotics and myoelectric orthotics. The change in Medicare reimbursement policy is a significant development for the industry, potentially opening up a larger market for companies like Myomo.

Comparison to Industry Standards

• Myomo's revenue growth of 20% in product sales is strong compared to the average growth rate in the medical device industry, which is typically in the single digits.
• The company's gross margin of 68.5% is competitive with other medical device companies, but may be lower than some high-margin specialty device manufacturers.
• The company's net loss, while still significant, is improving year-over-year, which is a positive trend compared to other early-stage medical device companies.
• The transition to lump sum Medicare reimbursement is a significant advantage for Myomo, as it aligns with the reimbursement model of commercial insurers, unlike companies that rely on rental models.
• The company's focus on direct billing and partnerships with O&P providers is a common strategy in the orthotics and prosthetics market, similar to companies like Ottobock and Össur, but with a focus on myoelectric technology.

Corporate Governance

Legal Proceedings

• The company settled an age discrimination claim with a former employee during the fourth quarter of 2023.

Related Party Transactions

• The company has a joint venture with Beijing Ryzur Medical Investment Co., Ltd., to manufacture and sell products in greater China.

Stakeholder Impact

• Shareholders: The company's revenue growth and path to profitability are positive for shareholders, but ongoing losses and risks remain.
• Employees: The company plans to hire more than 50 employees, which is positive for job creation and growth opportunities.
• Customers: The transition to lump sum Medicare reimbursement will improve access to the MyoPro for eligible patients.
• Suppliers: The company's reliance on a single third-party manufacturer for key subassemblies creates a risk for suppliers.
• Creditors: The company's improved financial position and access to capital are positive for creditors.

Next Steps

• The company plans to hire more than 50 employees by the end of the second quarter of 2024.
• The company will focus on increasing clinical, reimbursement, and manufacturing capacity to serve Medicare Part B beneficiaries.
• The company expects to introduce the MyoPro3 and MyoPal device for pediatric use at a future date.

Key Dates

Keywords

MyoPro, myoelectric orthotics, Medicare reimbursement, medical robotics, upper limb paralysis, neuromuscular disorders, healthcare, medical devices, rehabilitation, orthotics, prosthetics